Deze manier van doen stelt mij wel bijzonder teleur: eerst stellen dat ze nooit en te nimmer onder de $ 6 zullen emitteren, en dan met deze stelling hun reet afvegen.
Form 8-K for CHELSEA THERAPEUTICS INTERNATIONAL, LTD.
--------------------------------------------------------------------------------
29-Dec-2011
Entry into a Material Definitive Agreement, Financial St
Item 1.01. Entry into a Material Definitive Agreement.
As previously announced, on July 26, 2011, we entered into an amendment to our existing controlled equity offering sales agreement with Cantor Fitzgerald & Co., or Cantor, pursuant to which we could issue and sell up to 3,291,666 shares of our common stock from time to time through Cantor acting as agent and/or principal. On December 28, 2011, we entered into another amendment to the equity offering sales agreement to terminate the restriction that limited sales of our common stock to a purchase price of not less than $6.00 and to change the maximum amount of our common stock available for sale pursuant to the controlled equity offering sales agreement to a number of shares with an aggregate offering price of $19,750,000. No other terms of the equity offering sales agreement were amended.
The foregoing description of the amendment to the sales agreement is qualified in its entirety by reference to the full text of such amendment, a copy of which is filed herewith as Exhibit 10.16 to this Current Report on Form 8-K and is incorporated herein by reference. This Current Report on Form 8-K also incorporates by reference the amendment to the sales agreement into our shelf registration statement on Form S-3 (File No. 333-171628) previously filed with the SEC.